{"id":"0ab4bd529e59","type":"article","url":"https://hartvaat.nl/2018/10/16/doac-s-halveren-trombo-embolische-events-na-af-cardioversie-versus-warfarine/","title":"DOAC's halveren trombo-embolische events na AF-cardioversie versus warfarine","title_en":"Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["aperitif-trial","doacs","dubbele-trombocytenremming","veneuze-trombose"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2018.07.083","source_url":"https://doi.org/10.1016/j.jacc.2018.07.083","authors":["Dipak Kotecha","Charles V Pollack","Raffaele De Caterina","Giulia Renda","Paulus Kirchhof"],"significance":7,"published":"2018-10-16","source_date":"2018-10-16","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"This study showed that DOACs halve the risk of thromboembolic events after cardioversion for AF compared with warfarin, supporting DOAC-based anticoagulation as the preferred approach around cardioversion procedures.","created":"2026-07-03T10:27:33Z","updated":"2026-07-03T13:26:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie die aantoont dat DOAC's het risico op trombo-embolie na AF-cardioversie halveren vergeleken met warfarine. Ondersteunt DOAC-voorkeur rond cardioversie.","abstract_original":""}